Lanxess and energy company Engie have concluded power full supply agreements for a total of 1,400 GWh for five sites in Germany at Bergkamen, Bitterfeld, Brilon, Brunsbuettel and Mannheim, and two in Belgium (Lillo and Kallo) until the end of 2025.
Dow has outlined what it described as “a series of targeted actions aligned to its previously stated plan to achieve $1 billion in cost savings in 2023”. This is divided into $500 million each of ‘structural improvements’ and operating expense reductions. The measures include:
Cabot plans to invest about $75-90 million to add 15,000 tonnes/year of conductive carbon additives (CCA) capacity at its site in Pampa, Texas.
French greentech firm Afyren has signed a deal with Thailand’s Mitr Phol, the world’s third largest sugar producer, under which they will form a 70-30 joint venture to build a biorefinery at the latter’s site near Bangkok.
OQ Chemicals has begun an optimisation and debottlenecking project for carboxylic acids at its plants in Germany. Structural work has already commenced, with completion planned before the end of the Q1.
CordenPharma has signed a multi-year agreement for the contract manufacture of a large-volume launch peptide at its former Roche facility in Boulder, Colorado. This will begin in 2023 and will potentially be worth about $1 billion, depending on actual production levels required.
In response to an increasing number of projects, notably in oncology, Indian CRDMO Sai Life Sciences, has opened a 1,485 m2 high potency API (HPAPI) facility at its cGMP API campus in Bidar.
Current Issue
French CDMO Seqens has opened its $5 million ‘Seqens Boston R&D Center’ in Devens, Massachusetts, in pl
Subject to usual closing conditions, Japan’s Sumitomo Chemical is to acquire FBSciences, a US-based firm wh
Brenntag has revealed that it is collaborating with Chicago-based Project44 to create a platform via which
Lanxess and energy company Engie have concluded power full supply agreements for a total of 1,400 GWh for f
Most Popular
Pharmaceutical CDMOs are continuing to invest in a buoyant market. We report from CPHI Frankfurt
The mood among CDMOs remained buoyant at the rebranded CPHI Frankfurt show, which took place on 1-3 November. There were several announcements of major investments and most of the exhibitors SCM spoke to were optimistic about continued rapid growth, particularly in new modalities of all kinds.
CordenPharma has signed a multi-year agreement for the contract manufacture of a large-volume launch peptide at its former Roche facility in Boulder, Colorado. This will begin in 2023 and will potentially be worth about $1 billion, depending on actual production levels required. The customer has not been named and no further details are being disclosed.
Dow has outlined what it described as “a series of targeted actions aligned to its previously stated plan to achieve $1 billion in cost savings in 2023”. This is divided into $500 million each of ‘structural improvements’ and operating expense reductions. The measures include:
* About 2,000 job cuts to reduce labour and services costs
* Shutting down select assets, while further evaluating the asset base, particularly in Europe
* Increasing productivity via end-to-end process improvements
